Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Celldex Therapeutics (CLDX) Short Interest Ratio & Short Volume

Celldex Therapeutics logo
$30.72 +0.14 (+0.46%)
As of 02:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Celldex Therapeutics Short Interest Overview

As of April 30, 2026, Celldex Therapeutics (CLDX) had a short interest of 7.60 million shares sold short, representing 10.21% of the public float. This marks a -8.54% decrease in short interest since the prior report. The short interest ratio (days to cover) is 9.4, meaning it would take 9.4 days of the average trading volume of 911,297 shares to cover all short positions.

Current Short Interest
7,599,353 shares
Previous Short Interest
8,309,099 shares
Change Vs. Previous Month
-8.54%
Dollar Volume Sold Short
$249.87 million
Short Interest Ratio
9.4 Days to Cover
Last Record Date
April 30, 2026
Outstanding Shares
78,490,000 shares
Short Percent of Float
10.21%
Today's Trading Volume
235,392 shares
Average Trading Volume
911,297 shares
Today's Volume Vs. Average
26%
Short Selling Celldex Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Celldex Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CLDX Short Interest Over Time

CLDX Days to Cover Over Time

CLDX Percentage of Float Shorted Over Time

Celldex Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/20267,599,353 shares $249.87 million -8.5%10.2%9.41 $32.88
4/15/20268,309,099 shares $281.43 million -8.5%13.1%5.54 $33.87
3/31/20269,075,800 shares $287.88 million -1.8%14.3%8.49 $31.72
3/13/20269,237,012 shares $272.58 million +2.6%14.5%9.95 $29.51
2/27/20269,006,071 shares $270.99 million -1.9%14.2%8.44 $30.09
2/13/20269,181,713 shares $211.18 million -0.6%14.5%13.3 $23.00
1/30/20269,237,135 shares $227.23 million +2.2%14.5%19.42 $24.60
1/15/20269,034,401 shares $232.09 million +9.6%14.2%10.84 $25.69
12/31/20258,244,450 shares $223.92 million +20.1%13.0%12.26 $27.16
12/15/20256,865,432 shares $185.98 million -20.9%10.8%7.9 $27.09
11/28/20258,675,509 shares $234.20 million -1.9%13.7%13.27 $27.00
11/14/20258,845,278 shares $226.00 million +17.8%13.9%8.49 $25.55
10/31/20257,509,487 shares $200.73 million +1.5%11.8%10.41 $26.73
10/15/20257,400,000 shares $202.32 million +4.5%11.7%6.1 $27.34
9/30/20257,080,000 shares $183.16 million +7.6%N/A5.9 $25.87
9/15/20256,580,000 shares $161.21 million -8.7%N/A5.2 $24.50
8/31/20257,210,000 shares $159.20 million -1.4%11.4%5.7 $22.08
8/15/20257,310,000 shares $186.41 million -6.0%N/A6.1 $25.50
7/31/20257,780,000 shares $171.00 million -8.2%12.3%7.5 $21.98
7/15/20258,470,000 shares $193.54 million +7.6%N/A8.6 $22.85
6/30/20257,870,000 shares $160.15 million +0.5%12.4%7.9 $20.35
6/15/20257,830,000 shares $166.47 million -6.5%12.3%8.3 $21.26
5/31/20258,370,000 shares $163.13 million -8.3%13.1%9.6 $19.49
5/15/20259,130,000 shares $183.51 million +1.3%14.3%11.3 $20.10
4/30/20259,010,000 shares $187.68 million +2.6%N/A11.6 $20.83
4/15/20258,780,000 shares $161.29 million +5.8%13.8%11 $18.37
3/31/20258,300,000 shares $150.65 million -9.3%13.0%9.3 $18.15
3/15/20259,150,000 shares $186.84 million +3.0%14.3%10.5 $20.42
2/28/20258,880,000 shares $182.66 million -3.4%13.9%9.7 $20.57
2/15/20259,190,000 shares $208.61 million +3.6%14.4%9.8 $22.70
1/31/20258,870,000 shares $217.23 million +4.6%N/A8.8 $24.49
1/15/20258,480,000 shares $191.82 million +4.8%N/A8.2 $22.62
12/31/20248,090,000 shares $204.43 million +10.7%N/A8 $25.27
12/15/20247,310,000 shares $185.75 million -5.1%N/A6 $25.41
11/30/20247,700,000 shares $211.29 million -1.7%N/A6.5 $27.44
11/15/20247,830,000 shares $184.40 million -5.0%N/A6.8 $23.55
10/31/20248,240,000 shares $214.73 million -1.9%N/A7.7 $26.06
10/15/20248,400,000 shares $246.96 million +1.1%N/A8.3 $29.40
9/30/20248,310,000 shares $282.46 million -1.2%N/A8.5 $33.99
9/15/20248,410,000 shares $371.39 million -1.9%N/A11.4 $44.16
The SpaceX supplier that shipped 5 billion chips to Starlink (Ad)

When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off.tc pixel

Get the name and ticker before the SpaceX IPO arrives
8/31/20248,570,000 shares $354.20 million -1.0%N/A12.2 $41.33
8/15/20248,660,000 shares $286.65 million +3.1%N/A12.2 $33.10
7/31/20248,400,000 shares $320.12 million +13.7%N/A12.1 $38.11
7/15/20247,390,000 shares $292.27 million +5.7%N/A11.5 $39.55
6/30/20246,990,000 shares $258.70 million +8.7%N/A10.9 $37.01
6/15/20246,430,000 shares $222.93 million +2.6%N/A10.1 $34.67
5/31/20246,270,000 shares $208.79 million -5.3%N/A9.1 $33.30
5/15/20246,620,000 shares $265.93 million -5.3%N/A7.4 $40.17
4/30/20246,990,000 shares $261.57 million +3.6%N/A7.7 $37.42
4/15/20246,750,000 shares $263.72 million +2.9%N/A7.3 $39.07
3/31/20246,560,000 shares $275.32 million +11.2%N/A6.9 $41.97
3/15/20245,900,000 shares $247.86 million -8.0%N/A6.4 $42.01
2/29/20246,410,000 shares $308.06 million -7.6%N/A7.4 $48.06
2/15/20246,940,000 shares $255.39 million +3.4%N/A9.3 $36.80
1/31/20246,710,000 shares $236.33 million +7.9%N/A8.5 $35.22
1/15/20246,220,000 shares $261.49 million -5.6%N/A7.6 $42.04
12/31/20236,590,000 shares $261.36 million -10.3%N/A8.6 $39.66
12/15/20237,350,000 shares $273.05 million -8.9%N/A9.6 $37.15
11/30/20238,070,000 shares $243.79 million +2.4%N/A11.1 $30.21
11/15/20237,880,000 shares $224.82 million +40.2%N/A11.3 $28.53
10/31/20235,620,000 shares $132.18 million +0.9%N/A9.2 $23.52
10/15/20235,570,000 shares $145.60 million -3.3%N/A12.1 $26.14
9/30/20235,760,000 shares $158.52 million -5.4%N/A13.1 $27.52
9/15/20236,090,000 shares $170.22 million -3.3%N/A14.3 $27.95
8/31/20236,300,000 shares $175.77 million -3.7%N/A13.5 $27.90
8/15/20236,540,000 shares $205.55 million +8.5%N/A14.3 $31.43
7/31/20236,030,000 shares $213.22 million -3.8%N/A13.8 $35.36
7/15/20236,270,000 shares $233.81 million +1.8%N/A13.5 $37.29
6/30/20236,160,000 shares $209.01 million +2.7%N/A11 $33.93
6/15/20236,000,000 shares $221.22 million +3.5%N/A9.8 $36.87
5/31/20235,800,000 shares $184.44 million +7.0%N/A9.3 $31.80
5/15/20235,420,000 shares $185.69 million +1.1%N/A8.4 $34.26
4/30/20235,360,000 shares $168.52 million +3.5%N/A8.4 $31.44
4/15/20235,180,000 shares $156.90 million -1.7%N/A8.6 $30.29
3/31/20235,270,000 shares $189.61 million +38.0%N/A9.9 $35.98
3/15/20233,820,000 shares $167.13 million +5.5%N/A8 $43.75
2/28/20233,620,000 shares $154.90 million +4.3%N/A7.5 $42.79
2/15/20233,470,000 shares $148.79 million +4.5%N/A7.7 $42.88
1/31/20233,320,000 shares $146.28 million -4.3%N/A6.8 $44.06
1/15/20233,470,000 shares $159.69 million +1.8%N/A7 $46.02
12/30/20223,410,000 shares $151.98 million -17.2%N/A6.8 $44.57
12/15/20224,120,000 shares $182.47 million +1.7%N/A8 $44.29
11/30/20224,050,000 shares $150.21 million -1.9%N/A9 $37.09
11/15/20224,130,000 shares $151.53 million -8.2%N/A9 $36.69
10/31/20224,500,000 shares $158.09 million -0.9%N/A9.7 $35.13
10/15/20224,540,000 shares $142.74 million -1.5%N/A9.3 $31.44
9/30/20224,610,000 shares $129.59 million +2.4%N/A9 $28.11
9/15/20224,500,000 shares $136.40 million +2.3%N/A6.2 $30.31
8/31/20224,400,000 shares $133.76 million +4.0%N/A5.6 $30.40
8/15/20224,230,000 shares $158.92 million +14.3%N/A5.1 $37.57
Your book attached (Ad)

Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel

Download the Safe Trade Options Formula book for free before access closes
7/31/20223,700,000 shares $113.66 million -2.9%30.7%4.3 $30.72
7/15/20223,810,000 shares $111.79 million -0.3%31.6%4.5 $29.34
6/30/20223,820,000 shares $102.99 million -18.9%31.7%4.7 $26.96
6/15/20224,710,000 shares $104.99 million +1.5%39.0%7.3 $22.29
5/31/20224,640,000 shares $109.13 million -5.5%N/A8 $23.52
5/15/20224,910,000 shares $147.25 million -1.0%N/A8.7 $29.99
4/30/20224,960,000 shares $151.53 million -9.3%N/A9 $30.55
4/15/20225,470,000 shares $196.04 million -0.2%N/A9.8 $35.84
3/31/20225,480,000 shares $186.65 million -8.7%N/A9.3 $34.06
3/15/20226,000,000 shares $187.26 million +3.3%N/A10.3 $31.21
2/28/20225,810,000 shares $173.72 million +11.7%N/A10 $29.90
2/15/20225,200,000 shares $169.78 million +2.4%N/A9.4 $32.65
1/31/20225,080,000 shares $157.53 million +3.3%N/A9.9 $31.01
1/15/20224,920,000 shares $157.00 million +3.1%N/A0 $31.91
12/31/20214,770,000 shares $184.31 million +9.9%N/A10.6 $38.64
12/15/20214,340,000 shares $166.92 million +6.6%N/A10.1 $38.46
11/30/20214,070,000 shares $155.07 million +12.4%N/A9.7 $38.10
11/15/20213,620,000 shares $155.70 million -2.7%N/A8.2 $43.01
10/29/20213,720,000 shares $158.25 million +25.7%N/A7.9 $42.54
10/15/20212,960,000 shares $136.69 million -0.7%N/A5.7 $46.18
9/30/20212,980,000 shares $160.89 million -11.0%N/A3.8 $53.99
9/15/20213,350,000 shares $178.25 million -15.4%N/A3.7 $53.21
8/31/20213,960,000 shares $208.49 million -8.1%N/A4.4 $52.65
8/13/20214,310,000 shares $188.43 million +15.2%N/A4.9 $43.72
7/30/20213,740,000 shares $163.63 million +11.6%N/A4.5 $43.75
7/15/20213,350,000 shares $146.93 million +19.2%N/A4.2 $43.86
6/30/20212,810,000 shares $93.97 million +11.1%7.3%4.1 $33.44
6/15/20212,530,000 shares $73.88 million -18.4%6.6%4.4 $29.20
5/28/20213,100,000 shares $86.65 million -3.7%8.1%5.3 $27.95

CLDX Short Interest - Frequently Asked Questions

Short interest is the volume of Celldex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 7,599,353 shares of CLDX short. 10.21% of Celldex Therapeutics' shares are currently sold short. Learn More on Celldex Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLDX shares currently have a short interest ratio of 9.4. Learn More on Celldex Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.21% of Celldex Therapeutics' floating shares are currently sold short.

Celldex Therapeutics saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 7,599,353 shares, a drop of 8.5% from the previous total of 8,309,099 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

10.21% of Celldex Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Celldex Therapeutics: BioMarin Pharmaceutical Inc. (5.63%), Halozyme Therapeutics, Inc. (12.45%), Repligen Corporation (9.81%), Alkermes plc (12.43%), Ligand Pharmaceuticals Incorporated (7.81%), BioCryst Pharmaceuticals, Inc. (15.51%), Innoviva, Inc. (8.66%), Novavax, Inc. (30.39%), Zenas BioPharma, Inc. (24.25%), MannKind Corporation (9.88%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($86.09 billion), Invesco QQQ ($39.89 billion), iShares Russell 2000 ETF ($26.13 billion), Western Digital Corporation ($12.66 billion), Salesforce Inc. ($12.29 billion), Sandisk Corporation ($11.87 billion), SPDR S&P Biotech ETF ($9.82 billion), Lumentum Holdings Inc. ($8.51 billion), iShares 20+ Year Treasury Bond ETF ($7.76 billion), and Bloom Energy Corporation ($7.40 billion). View all of the most shorted stocks.

Short selling CLDX is an investing strategy that aims to generate trading profit from Celldex Therapeutics as its price is falling. CLDX shares are trading up $0.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Celldex Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CLDX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLDX, twice per month. The most recent reporting period available is April, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CLDX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:CLDX) was last updated on 5/22/2026 by MarketBeat.com Staff.
From Our Partners
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
Maybe the Greatest Strategy of the Decade
Nate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...
Monument Traders Alliance | Sponsoredtc pixel
To Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy Tech
President Trump has used emergency executive powers to back a new energy technology described as 326 times mor...
Altimetry | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
Hidden on Tesla's filing: A $12 billion "super startup"
Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...
Banyan Hill Publishing | Sponsoredtc pixel